BOSCHEINEN, OLIVER,DREYER, MATTHIAS,HABERMANN, PAUL,SCHAEFER, HANS-LUDWIG,SOMMERFELD, MARK,LANGER, THOMAS
申请号：
HK15107811.5
公开号：
HK1207097A
申请日:
2015.08.13
申请国别(地区):
HK
年份:
2016
代理人:
摘要：
The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.
